Circio Announces Strengthened In Vivo Data for its circVec-AAV Gene Expression System

OSLO, Norway, August 28, 2025 – Circio Holding ASA, a biotechnology company specializing in circular RNA technology, announced today that it is presenting strengthened in vivo data for its proprietary circVec-AAV expression system. The new data demonstrates a significant advantage in gene expression for its next-generation technology.

The company’s Chief Technology Officer, Dr. Thomas B. Hansen, will present the latest results, which show that the new circVec generation 3.2 can achieve up to a 40-fold protein expression level advantage in the heart when compared to conventional mRNA-based AAVs. This encouraging data from a prior study has now been validated in a larger repeat experiment.

In parallel, Circio has characterized the performance of its circVec-AAVs in other tissues, identifying a 15-fold expression advantage in the eye. The company is currently conducting broader in vivo testing for this application.

According to Dr. Hansen, a major challenge with conventional AAV gene therapy is the need for extremely high doses, which can lead to toxicity and increased manufacturing costs. “Our current data package suggests that switching to circVec-based expression may enable 10-fold, or more, dose reduction, which would be a major breakthrough for the AAV gene therapy field,” he said. The company also announced it has continued to implement tight cost controls and has secured funding through the end of 2025.